ES2902014T3 - Método de diagnóstico y medicina que comprende ADAMTS13 como ingrediente principal - Google Patents

Método de diagnóstico y medicina que comprende ADAMTS13 como ingrediente principal Download PDF

Info

Publication number
ES2902014T3
ES2902014T3 ES17736035T ES17736035T ES2902014T3 ES 2902014 T3 ES2902014 T3 ES 2902014T3 ES 17736035 T ES17736035 T ES 17736035T ES 17736035 T ES17736035 T ES 17736035T ES 2902014 T3 ES2902014 T3 ES 2902014T3
Authority
ES
Spain
Prior art keywords
adamts13
liver
activity
vwf
transplantation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17736035T
Other languages
English (en)
Spanish (es)
Inventor
Koichiro Hata
Shinji Uemoto
Hirofumi Hirao
Toyonari Kubota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
KM Biologics Co Ltd
Original Assignee
Kyoto University
KM Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University, KM Biologics Co Ltd filed Critical Kyoto University
Application granted granted Critical
Publication of ES2902014T3 publication Critical patent/ES2902014T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17736035T 2016-01-08 2017-01-06 Método de diagnóstico y medicina que comprende ADAMTS13 como ingrediente principal Active ES2902014T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016002685 2016-01-08
PCT/JP2017/000316 WO2017119498A1 (fr) 2016-01-08 2017-01-06 Agent diagnostique et médicament comprenant adamts13 comme ingrédient principal

Publications (1)

Publication Number Publication Date
ES2902014T3 true ES2902014T3 (es) 2022-03-24

Family

ID=59273878

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17736035T Active ES2902014T3 (es) 2016-01-08 2017-01-06 Método de diagnóstico y medicina que comprende ADAMTS13 como ingrediente principal

Country Status (6)

Country Link
US (3) US11567080B2 (fr)
EP (1) EP3401685B1 (fr)
JP (2) JP7002727B2 (fr)
CN (1) CN108463729B (fr)
ES (1) ES2902014T3 (fr)
WO (1) WO2017119498A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858689B2 (en) 2016-10-11 2020-12-08 Laboratory Corporation Of America Holdings Methods and systems for determining ADAMTS13 enzyme activity
JP7359775B2 (ja) * 2018-09-14 2023-10-11 テルモ株式会社 循環器障害または血栓形成の進行またはそのリスクの予測
EP4037704A4 (fr) * 2019-10-04 2023-04-26 The Children's Medical Center Corporation Traitement à base d'adamts13 pour améliorer la survie de greffon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499926C (fr) 2002-09-25 2013-06-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticorps dirige contre l'enzyme clivant du facteur von willebrand et systeme de dosage utilisant cet anticorps
JP4369143B2 (ja) * 2003-02-28 2009-11-18 学校法人慶應義塾 フォンビルブランド因子切断酵素機能の検出方法
EP1488798A1 (fr) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composition de polypeptide HIP/PAP pour utilisation dans la régénération du foie et dans la prévention de l'insuffisance hépatique
CA2550939A1 (fr) 2003-12-22 2005-07-07 Mitsubishi Kagaku Iatron, Inc. Procede permettant de detecter la thrombose en mesurant l'enzyme clivant le facteur de von willebrand
JP4875495B2 (ja) 2004-11-08 2012-02-15 三菱化学メディエンス株式会社 血小板血栓症又は臓器障害の検出方法
WO2006133955A1 (fr) 2005-06-17 2006-12-21 Baxter International Inc. Compositions contenant adamts13, presentant une activite thrombolytique
US20090004673A1 (en) 2006-01-31 2009-01-01 Mitsubishi Kagaku Iatron, Inc. Method for Determining Condition of Disseminated Intravascular Coagulation
JP2009539757A (ja) 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
JP5411582B2 (ja) 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
HU0900534D0 (en) * 2009-08-29 2009-10-28 Semmelweis Egyetem Method and kit for improvement of prognosing of heart failure
EA024267B1 (ru) 2009-09-21 2016-09-30 Баксалта Инкорпорейтид Стабилизированные жидкие и лиофилизированные композиции adamts13
JP5648905B2 (ja) 2010-11-12 2015-01-07 株式会社Ｌｓｉメディエンス 肝臓がん発症の検出又はリスクの予測方法
JP6419576B2 (ja) * 2011-11-11 2018-11-07 イムコア ジーティーアイ ダイアグノスティクス インコーポレイテッド プロテアーゼａｄａｍｔｓ１３を切断するフォン・ヴィレブランド因子の検出用ポリペプチド基体
CN102533937A (zh) * 2012-02-03 2012-07-04 苏州大学附属第一医院 一种检测adamts13酶活性的荧光底物及检测方法
CN103808944B (zh) * 2014-03-07 2016-04-20 高平 生物标志物vwf和adamts13及其在肝硬化诊断试剂中的用途

Also Published As

Publication number Publication date
CN108463729A (zh) 2018-08-28
WO2017119498A1 (fr) 2017-07-13
CN108463729B (zh) 2021-03-19
US11567080B2 (en) 2023-01-31
JP7002727B2 (ja) 2022-02-15
EP3401685A4 (fr) 2020-02-12
EP3401685B1 (fr) 2021-12-01
JP7385221B2 (ja) 2023-11-22
US20240159751A1 (en) 2024-05-16
US20200284793A1 (en) 2020-09-10
EP3401685A1 (fr) 2018-11-14
JPWO2017119498A1 (ja) 2018-12-13
US20230168251A1 (en) 2023-06-01
EP3988938A1 (fr) 2022-04-27
JP2021129565A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
US20240159751A1 (en) Diagnostic agent and medicine comprising adamts13 as main ingredient
Yang et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy
Zhu et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation
Noubouossie et al. Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies
Fu et al. Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration
Tan et al. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers
Shmuel-Galia et al. Dysbiosis exacerbates colitis by promoting ubiquitination and accumulation of the innate immune adaptor STING in myeloid cells
Remuzzi et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
RU2705786C2 (ru) Gla домены в качестве терапевтических агентов
Noris et al. Thrombotic thrombocytopenic purpura-then and now
JP2019037242A (ja) 出血性障害の治療に対する改変セルピン
Hashimoto et al. Annexin V homodimer protects against ischemia reperfusion–induced acute lung injury in lung transplantation
Larsson et al. Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse
US20180188270A1 (en) Diagnostic test for alzheimer's disease based on identification of a proteolytic pathway
Kiouptsi et al. Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels
GALBUSERA et al. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
EP3988938B1 (fr) Médicament comprenant adamts13 comme ingrédient principal
Machado et al. Modulation of extravascular binding of recombinant factor IX impacts the duration of efficacy in mouse models
WO2016205595A1 (fr) Procédés associés au traitement de la colite et des maladies inflammatoires de l'intestin
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
ES2883952T3 (es) Clusterina para su uso en el tratamiento de microangiopatías trombóticas
Tsai Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndromes
Bazzi Role of Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Metastasis and Angiogenesis
US20180256571A1 (en) Methods relating to the diagnosis and treatment of thrombotic microangiopathy
Melis et al. Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain